Healthcare Industry News: Ironwood Pharmaceuticals
News Release - August 21, 2013
Ironwood Pharmaceuticals Appoints Dr. Michael Hall as Senior Vice President of Clinical DevelopmentCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Ironwood Pharmaceuticals, Inc. (IRWD) today announced that Michael Hall, MB. BCh., has joined the company as senior vice president of clinical development. Dr. Hall will lead Ironwood’s clinical research, clinical development, clinical operations, biostatistics and pharmacovigilance teams. In this role, he will oversee clinical trials investigating additional appropriate populations for linaclotide, as well as Ironwood’s pipeline of early development candidates.
“Michael’s unique combination of drug development experience, deep scientific knowledge, patient-oriented medical perspective, and proven leadership capabilities will be of significant value in supporting our clinical development activities,” said Mark Currie, Ph.D., senior vice president, chief scientific officer, and president of research and development at Ironwood. “We feel very fortunate to welcome Michael to our team.”
Prior to joining Ironwood, Dr. Hall served as chief medical officer and senior vice president at Repligen Corp., where he oversaw the advancement of late-stage programs through registration application and early-stage programs into the clinic. He previously served as vice president of global clinical affairs at Shire Human Genetic Therapies, where he led clinical research, clinical operations and biostatistics, and he established a translational medicine group supporting the early clinical and business development teams that was instrumental in the in-licensing of multiple products. Dr. Hall previously held medical affairs, pharmacovigilance and clinical positions at Novartis Pharmaceuticals Corp. Prior to joining the pharmaceutical industry, Dr. Hall worked at Hillbrow Hospital and Johannesburg General Hospital, both in Johannesburg. He earned his MB. BCh. medical degree from the University of Witwatersrand Medical School in Johannesburg.
“The discipline with which the team at Ironwood advances programs and the degree to which they focus on science that addresses unmet needs of patients were driving factors in my decision to join the company,” said Dr. Hall. “I look forward to adding my clinical development and medical expertise to the passionate and experienced team of pharmacologists and business leaders at Ironwood.”
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (IRWD) is committed to the art and science of making medicines, from discovery through commercialization. We’re focused on three goals: transforming knowledge into medicines that make a difference for patients, creating value that will inspire the continued support of our fellow shareholders, and building a team that passionately pursues excellence. Our first product, linaclotide, is approved in the United States and Europe. Our pipeline priorities include exploring further opportunities for linaclotide, leveraging our deep expertise in functional gastrointestinal disorders, and advancing programs in other areas such as allergic conditions, cardiovascular disease, central nervous system disorders and other conditions defined by patient symptoms. Ironwood was founded in 1998 and is headquartered in Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at www.twitter.com/ironwoodpharma to learn more about Ironwood. Information that may be important to investors will be routinely posted in both these locations.
Source: Ironwood Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.